

# **Boehringer Ingelheim Foundation: New Managing Directors**

Mainz, 17 April 2020: Due to the current size of the non-profit Boehringer Ingelheim Foundation and its desire to expand its areas of activity, the foundation's Executive Committee has decided to appoint two new managing directors.

As of 1 May 2020, Mr Marc Wittstock will assume the newly created position of Managing Director Finance & Administration of the Boehringer Ingelheim Foundation (BIS), Mainz. After twelve successful years with different responsibilities in the area of Finance & Controlling – most recently as Head of Corporate Treasury – Mr Wittstock has decided to pursue a career opportunity outside the Boehringer Ingelheim Company Group and will resign from his position there at the end of April 2020.

Effective 1 July 2020, Dr Stephan Formella will become Managing Director Science & Research of the Boehringer Ingelheim Foundation, also a newly created position. For 16 years, Dr Formella has successfully served in different positions in the field of translational medicine at Boehringer Ingelheim Company, most recently as Head of Early Clinical Operations.

Since 2009, the Boehringer Ingelheim Foundation has been run by Dr Claudia Walther, Managing Director of the Boehringer Ingelheim Fonds, Foundation for Basic Research in Medicine.

Together with Mr Wittstock, Dr Walther will continue to direct the Boehringer Ingelheim Foundation until 30 June 2020. Afterwards she will devote herself to her responsibilities at the Boehringer Ingelheim Fonds and continue to look after the Siblings Boehringer Ingelheim Foundation for the Humanities. During her tenure as Managing Director, she has played an important role in developing and expanding the Boehringer Ingelheim Foundation. She strongly supported the founding and the establishment of the Mainz Institute of Molecular Biology (IMB), developed new funding programmes in the life sciences, and successfully represented the Foundation in the German foundation sector. Her experience and expertise in the life sciences, research funding, and the foundation sector were and continue to be highly valued in the international scientific and foundation community.

We wish to thank Dr Walther for her previous work and look forward to working together with Mr Wittstock and Dr Formella. We wish all of them continued success.

#### (sgd.) Christoph Boehringer

Chairman of the Executive Committee of the Boehringer Ingelheim Foundation

#### (sgd.) Prof. Dr Dr Andreas Barner


Chairman of the Board of Trustees of the Boehringer Ingelheim Fonds and Member of the Executive Committee of the Boehringer Ingelheim Foundation

### **Boehringer Ingelheim Foundation**

The Boehringer Ingelheim Foundation is an independent, non-profit organization committed to the promotion of the medical, biological, chemical, and pharmaceutical sciences. It was established in 1977 by Hubertus Liebrecht (1931–

## **Boehringer Ingelheim Stiftung**

Schusterstraße 46-48
55116 Mainz
Telefon 06131 27 50 8 12
Telefax 06131 27 50 8 11
secretariat@bistiftung.de
www.boehringer-ingelheim-stiftung.de



1991), a member of the shareholder family of the Boehringer Ingelheim group of companies. With the Perspectives Programme Plus 3 and the Exploration Grants, the Foundation supports excellent independent junior group leaders. It also endows the internationally renowned Heinrich Wieland Prize as well as awards for up-and-coming scientists. In addition, the Foundation is donating a total of 154 million euros from 2009 to 2027 to the University of Mainz to finance the scientific operations of the Institute of Molecular Biology (IMB). Since 2013, the Foundation has been providing a further 50 million euros for the development of the life sciences at the University of Mainz.

www.boehringer-ingelheim-stiftung.de/en

Tel.: +49 (0) 6131 27508-12 Email: secretariat@bistiftung.de www.boehringer-ingelheim-stiftung.de